180 related articles for article (PubMed ID: 29549312)
41. The autotaxin-lysophosphatidic acid pathway in pathogenesis of rheumatoid arthritis.
Orosa B; García S; Conde C
Eur J Pharmacol; 2015 Oct; 765():228-33. PubMed ID: 26297977
[TBL] [Abstract][Full Text] [Related]
42. Production of bioactive lysophosphatidic acid by lysophospholipase D in hen egg white.
Morishige J; Touchika K; Tanaka T; Satouchi K; Fukuzawa K; Tokumura A
Biochim Biophys Acta; 2007 Apr; 1771(4):491-9. PubMed ID: 17321793
[TBL] [Abstract][Full Text] [Related]
43. Increased production of bioactive lysophosphatidic acid by serum lysophospholipase D in human pregnancy.
Tokumura A; Kanaya Y; Miyake M; Yamano S; Irahara M; Fukuzawa K
Biol Reprod; 2002 Nov; 67(5):1386-92. PubMed ID: 12390867
[TBL] [Abstract][Full Text] [Related]
44. Identification and pharmacological characterization of a novel inhibitor of autotaxin in rodent models of joint pain.
Thirunavukkarasu K; Swearingen CA; Oskins JL; Lin C; Bui HH; Jones SB; Pfeifer LA; Norman BH; Mitchell PG; Chambers MG
Osteoarthritis Cartilage; 2017 Jun; 25(6):935-942. PubMed ID: 27638130
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of serum ATX and LPA as potential diagnostic biomarkers in patients with pancreatic cancer.
Chen J; Li H; Xu W; Guo X
BMC Gastroenterol; 2021 Feb; 21(1):58. PubMed ID: 33568105
[TBL] [Abstract][Full Text] [Related]
46. Lysophosphatidylcholines modulate immunoregulatory checkpoints in peripheral monocytes and are associated with mortality in people with acute liver failure.
Trovato FM; Zia R; Artru F; Mujib S; Jerome E; Cavazza A; Coen M; Wilson I; Holmes E; Morgan P; Singanayagam A; Bernsmeier C; Napoli S; Bernal W; Wendon J; Miquel R; Menon K; Patel VC; Smith J; Atkinson SR; Triantafyllou E; McPhail MJW
J Hepatol; 2023 Mar; 78(3):558-573. PubMed ID: 36370949
[TBL] [Abstract][Full Text] [Related]
47. Extracellular and intracellular productions of lysophosphatidic acids and cyclic phosphatidic acids by lysophospholipase D from exogenously added lysophosphatidylcholines to cultured NRK52E cells.
Tsutsumi T; Kawabata K; Yamazaki N; Tsukigawa K; Nishi H; Tokumura A
Biochim Biophys Acta Mol Cell Biol Lipids; 2023 Sep; 1868(9):159349. PubMed ID: 37295607
[TBL] [Abstract][Full Text] [Related]
48. Presence of bioactive lysophosphatidic acid in renal effluent of rats with unilateral ureteral obstruction.
Tsutsumi T; Adachi M; Nikawadori M; Morishige J; Tokumura A
Life Sci; 2011 Aug; 89(5-6):195-203. PubMed ID: 21693124
[TBL] [Abstract][Full Text] [Related]
49. The Autotaxin-Lysophosphatidic Acid Axis Promotes Lung Carcinogenesis.
Magkrioti C; Oikonomou N; Kaffe E; Mouratis MA; Xylourgidis N; Barbayianni I; Megadoukas P; Harokopos V; Valavanis C; Chun J; Kosma A; Stathopoulos GT; Bouros E; Bouros D; Syrigos K; Aidinis V
Cancer Res; 2018 Jul; 78(13):3634-3644. PubMed ID: 29724718
[TBL] [Abstract][Full Text] [Related]
50. [Laboratory-Based Clinical Research I am Aiming for].
Yatomi Y
Rinsho Byori; 2014 Nov; 62(11):1052-5. PubMed ID: 27509720
[TBL] [Abstract][Full Text] [Related]
51. Increased aqueous autotaxin and lysophosphatidic acid levels are potential prognostic factors after trabeculectomy in different types of glaucoma.
Igarashi N; Honjo M; Kurano M; Yatomi Y; Igarashi K; Kano K; Aoki J; Aihara M
Sci Rep; 2018 Jul; 8(1):11304. PubMed ID: 30054520
[TBL] [Abstract][Full Text] [Related]
52. Benzoxaboroles-Novel Autotaxin Inhibitors.
Kraljić K; Jelić D; Žiher D; Cvrtila A; Dragojević S; Sinković V; Mesić M
Molecules; 2019 Sep; 24(19):. PubMed ID: 31547058
[TBL] [Abstract][Full Text] [Related]
53. Dexamethasone decreases the autotaxin-lysophosphatidate-inflammatory axis in adipose tissue: implications for the metabolic syndrome and breast cancer.
Meng G; Tang X; Yang Z; Zhao Y; Curtis JM; McMullen TPW; Brindley DN
FASEB J; 2019 Feb; 33(2):1899-1910. PubMed ID: 30192654
[TBL] [Abstract][Full Text] [Related]
54. Autotaxin (lysoPLD/NPP2) protects fibroblasts from apoptosis through its enzymatic product, lysophosphatidic acid, utilizing albumin-bound substrate.
Song J; Clair T; Noh JH; Eun JW; Ryu SY; Lee SN; Ahn YM; Kim SY; Lee SH; Park WS; Yoo NJ; Lee JY; Nam SW
Biochem Biophys Res Commun; 2005 Nov; 337(3):967-75. PubMed ID: 16219296
[TBL] [Abstract][Full Text] [Related]
55. Autotaxin overexpression causes embryonic lethality and vascular defects.
Yukiura H; Kano K; Kise R; Inoue A; Aoki J
PLoS One; 2015; 10(5):e0126734. PubMed ID: 25992708
[TBL] [Abstract][Full Text] [Related]
56. Development of lysophosphatidic acid pathway modulators as therapies for fibrosis.
Budd DC; Qian Y
Future Med Chem; 2013 Oct; 5(16):1935-52. PubMed ID: 24175745
[TBL] [Abstract][Full Text] [Related]
57. Evidence for de novo synthesis of lysophosphatidic acid in the spinal cord through phospholipase A2 and autotaxin in nerve injury-induced neuropathic pain.
Ma L; Uchida H; Nagai J; Inoue M; Aoki J; Ueda H
J Pharmacol Exp Ther; 2010 May; 333(2):540-6. PubMed ID: 20123931
[TBL] [Abstract][Full Text] [Related]
58. Optimization of a pipemidic acid autotaxin inhibitor.
Hoeglund AB; Bostic HE; Howard AL; Wanjala IW; Best MD; Baker DL; Parrill AL
J Med Chem; 2010 Feb; 53(3):1056-66. PubMed ID: 20041668
[TBL] [Abstract][Full Text] [Related]
59. Serum autotaxin is not a useful biomarker for ovarian cancer.
Nakamura K; Igarashi K; Ohkawa R; Yokota H; Masuda A; Nakagawa S; Yano T; Ikeda H; Aoki J; Yatomi Y
Lipids; 2012 Sep; 47(9):927-30. PubMed ID: 22700442
[TBL] [Abstract][Full Text] [Related]
60. Different origins of lysophospholipid mediators between coronary and peripheral arteries in acute coronary syndrome.
Kurano M; Kano K; Dohi T; Matsumoto H; Igarashi K; Nishikawa M; Ohkawa R; Ikeda H; Miyauchi K; Daida H; Aoki J; Yatomi Y
J Lipid Res; 2017 Feb; 58(2):433-442. PubMed ID: 28007846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
